Becton, Dickinson and Company logo
BDXBecton, Dickinson and Company

The forward PE ratio is 11.96 as of Thursday, July 9, 2026.

Forward PE Ratio (11.96) = Close Price ($150.85) / Consensus Forward EPS ($12.59)

BDX Forward PE Ratio Metrics

FORWARD PE RATIO

11.96

BDX Competitors' Forward PE Ratio

BDX

Becton, Dickinson and Company

Current

Market Cap

$54.65B

Forward PE Ratio

11.96

CAH

Cardinal Health, Inc.

vs BDX

Market Cap

$54.75B

Forward PE Ratio

22.02

EW

Edwards Lifesciences Corporation

vs BDX

Market Cap

$52.59B

Forward PE Ratio

31.10

COR

Cencora, Inc.

vs BDX

Market Cap

$58.85B

Forward PE Ratio

17.41

HUM

Humana Inc.

vs BDX

Market Cap

$47.76B

Forward PE Ratio

44.80

IDXX

IDEXX Laboratories, Inc.

vs BDX

Market Cap

$44.06B

Forward PE Ratio

37.91

BSX

Boston Scientific Corporation

vs BDX

Market Cap

$66.87B

Forward PE Ratio

13.33

REGN

Regeneron Pharmaceuticals, Inc.

vs BDX

Market Cap

$68.81B

Forward PE Ratio

14.31

A

Agilent Technologies, Inc.

vs BDX

Market Cap

$37.73B

Forward PE Ratio

21.31

IQV

IQVIA Holdings Inc.

vs BDX

Market Cap

$34.88B

Forward PE Ratio

15.90

Trailing vs Forward

Trailing P/E

38.1

reported TTM EPS

Forward P/E

12.0

consensus next-FY EPS

The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $12.59 implies +218.7% EPS growth vs the reported trailing $3.95.

Forward P/E by Fiscal Year

View All Analyst Estimates

At today's $150.85 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.

Fiscal year endConsensus EPSEstimate rangeAnalystsImplied P/E
2026-09-30$12.59$12.26 – $12.90812.0x
2027-09-30$13.40$12.96 – $14.15811.3x
2028-09-30$14.29$14.11 – $14.75110.6x

Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.

Forward PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Forward PE Ratio FAQ

What is the forward PE ratio for Becton, Dickinson and Company (BDX)?
The forward PE ratio for BDX stock is 11.96.

About Becton, Dickinson and Company

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Franklin Lakes, NJ
70,000 employees
Healthcare / Medical - Instruments & Supplies
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Thomas E. Polen Jr.